Literature DB >> 16123813

The NORSE (new-onset refractory status epilepticus) syndrome: defining a disease entity.

E P V Wilder-Smith1, E C H Lim, H L Teoh, V K Sharma, J J H Tan, B P L Chan, B K C Ong.   

Abstract

INTRODUCTION: To characterise a homogeneous group of patients with new-onset refractory status epilepticus (NORSE syndrome).
MATERIALS AND METHODS: This is a descriptive, semiprospective review of all cases of NORSE syndrome seen between 2000 and 2004 at a tertiary care public hospital in Singapore. A review of the literature was performed to identify possible additional similar cases for comparison.
RESULTS: Seven patients with NORSE syndrome were identified. Characterising features were female gender, young age, previous good health, cerebrospinal fluid pleocytosis (in 4), antecedent febrile illness (in 5), extraordinarily prolonged status epilepticus (average 32 days), failure of extensive investigations to reveal an underlying cause, catastrophic outcome as well as temporal lobe and leptomeningeal abnormality on brain magnetic resonance imaging. A review of the literature identified 12 similar patients, comprising both adults and children.
CONCLUSIONS: Based on our patients and those described in the literature, we characterise the NORSE syndrome. Increased recognition of this clinical entity is needed to help delineate the underlying aetiology of this unique severe illness.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16123813

Source DB:  PubMed          Journal:  Ann Acad Med Singap        ISSN: 0304-4602            Impact factor:   2.473


  36 in total

Review 1.  Immunity and inflammation in status epilepticus and its sequelae: possibilities for therapeutic application.

Authors:  Annamaria Vezzani; Raymond Dingledine; Andrea O Rossetti
Journal:  Expert Rev Neurother       Date:  2015       Impact factor: 4.618

2.  Prolonged refractory status epilepticus with early and persistent restricted hippocampal signal MRI abnormality.

Authors:  Laurent Chevret; Beatrice Husson; Seraphin Nguefack; Astrid Nehlig; Viviane Bouilleret
Journal:  J Neurol       Date:  2008-01-22       Impact factor: 4.849

Review 3.  Refractory and super-refractory status epilepticus--an update.

Authors:  Sara Hocker; William O Tatum; Suzette LaRoche; W David Freeman
Journal:  Curr Neurol Neurosci Rep       Date:  2014-06       Impact factor: 5.081

4.  A NORSE With No Name.

Authors:  David Spencer
Journal:  Epilepsy Curr       Date:  2016 Sep-Oct       Impact factor: 7.500

5.  NORSE Versus FIRES: What's in a Name?

Authors:  Katherine Nickels
Journal:  Epilepsy Curr       Date:  2018 Sep-Oct       Impact factor: 7.500

6.  New-onset refractory status epilepticus: Etiology, clinical features, and outcome.

Authors:  Nicolas Gaspard; Brandon P Foreman; Vincent Alvarez; Christian Cabrera Kang; John C Probasco; Amy C Jongeling; Emma Meyers; Alyssa Espinera; Kevin F Haas; Sarah E Schmitt; Elizabeth E Gerard; Teneille Gofton; Peter W Kaplan; Jong W Lee; Benjamin Legros; Jerzy P Szaflarski; Brandon M Westover; Suzette M LaRoche; Lawrence J Hirsch
Journal:  Neurology       Date:  2015-08-21       Impact factor: 9.910

Review 7.  Treatment of Super-Refractory Status Epilepticus.

Authors:  Ahmad Bayrlee; Nimalya Ganeshalingam; Lisa Kurczewski; Gretchen M Brophy
Journal:  Curr Neurol Neurosci Rep       Date:  2015-10       Impact factor: 5.081

8.  Plasma Exchange as a Therapeutic Modality in a Rare Case of Cryptogenic New Onset Refractory Status Epilepticus (NORSE).

Authors:  Manisha Shrivastava; Smita Chouhan; Seema Navaid
Journal:  J Clin Diagn Res       Date:  2017-07-01

9.  Unusual cause of fever, vision loss and super refractory status epilepticus in association with simian virus 40 (SV40).

Authors:  Ayush Agarwal; Deepti Vibha; Rohan Chawla; Mehar Chand Sharma
Journal:  BMJ Case Rep       Date:  2018-10-12

10.  Treatment of status epilepticus: an international survey of experts.

Authors:  James J Riviello; Jan Claassen; Suzette M LaRoche; Michael R Sperling; Brian Alldredge; Thomas P Bleck; Tracy Glauser; Lori Shutter; David M Treiman; Paul M Vespa; Rodney Bell; Gretchen M Brophy
Journal:  Neurocrit Care       Date:  2013-04       Impact factor: 3.210

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.